| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Lapatinib |
| Brand | Tyverb® |
| Indication | For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer. |
| Assessment Process | |
| Full pharmacoeconomic assessment commissioned by HSE | 03/12/2007 |
| NCPE assessment completed | 28/01/2008 |
| NCPE assessment outcome | Reimbursement recommended. |
Lapatinib could be considered cost-effective in Ireland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.